Dennis Fenton is an independent consultant after retiring from his 26 year career at Amgen.
Dennis joined the Abzena Board in 2022.
Dennis has over 40 years’ experience in the pharmaceutical industry with positions of increasing responsibility at companies including Pfizer and Amgen where he led both a Sales and Marketing Team and an Operations Team. His experience extends into 5 US patents for areas including the production and purification of products made by bioprocessing.
Dennis is on the Board of directors of Anaptysbio, Modern Meadow and Synedgen as well as previously serving on the Board of numerous other companies including Portola Pharmaceuticals, Siennia Biopharmaceuticals, Pfenex, Kythera Biopharmaceuticals, Hospira, Dendreon, XenoPort and Genzyme.
Dennis was granted a Ph.D. in Microbiology from Rutgers University, New Jersey, USA.